- Data presented today at the
- Approximately one-third of patients had no migraines, (achieved 100% reduction of migraine days) on average per month, with 300 mg of eptinezumab
“The encouraging and consistent results from the PROMISE 1 trial showing that eptinezumab provided both immediate and long-term efficacy over a period of a year, reinforce our confidence in eptinezumab’s potential to be a meaningful new treatment option for migraine prevention,” said
Highlights from PROMISE 1 Trial Following Third and Fourth Eptinezumab Infusions:
- Following the first quarterly infusion, patients treated with 300 mg experienced 4.3 fewer MMDs from a baseline of 8 MMDs, compared to 3.2 fewer MMDs for placebo from baseline (p value = 0.0001). At one year after the third and fourth quarterly infusions, patients treated with 300 mg experienced further gains in efficacy with a reduction of 5.2 fewer MMDs compared to 4.0 fewer MMDs for placebo-treated patients.*
- Approximately, 31 percent of patients achieved, on average per month, 100 percent reduction of migraine days from baseline compared to approximately 21 percent for placebo. This means that almost one-third of patients, on average, experienced monthly migraine freedom when treated with 300 mg of eptinezumab.
- There were no new safety findings observed with the third and fourth quarterly infusions.
“These data are very encouraging, especially for the majority of my patients who have struggled to find relief from traditional treatment options and have discontinued use either due to lack of efficacy or side effects,” said
The observed safety profile for PROMISE 1, to date, is consistent with previously reported eptinezumab studies. The most commonly reported adverse events occurring at an incidence of 2.0 percent or greater across all eptinezumab treatment groups and greater than placebo were: upper respiratory tract infection (10.5 percent), nasopharyngitis (common cold) (6.8 percent), fatigue (3.2 percent), diarrhea (2.3 percent) and oropharyngeal (mouth) pain (2.0 percent).
Migraine is a highly symptomatic and debilitating disease affecting a large patient population.1 Preventative treatments, if effective, may take weeks to months to achieve meaningful clinical benefits, and fail to meet the needs of most patients.2 Further, up to 80 percent of patients discontinue use within six months to a year due to lack of efficacy and/or side effects.3,4
Eptinezumab is an investigational monoclonal antibody discovered and developed by
About Eptinezumab PROMISE Clinical Trial Program
PROMISE 1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 1) was a Phase 3 randomized, double-blind, placebo-controlled global trial evaluating the safety and efficacy of eptinezumab for episodic migraine prevention. In the study, patients were randomized and 888 received eptinezumab (300 mg, 100 mg or 30mg), administered by infusion once every 12 weeks. To be eligible for the trial, patients must have experienced at most 14 headache days per month, of which at least four met the criteria for migraine. The primary endpoint was the mean change from baseline in monthly migraine days over the 12 week treatment period. Secondary study endpoints assessed through 12 weeks include at least 75 percent and at least 50 percent responder rates, proportion of patients experiencing migraine on the day following administration, and those assessed through week 24 include at least 75 percent and 100 percent responder rates. In June 2017, Alder announced that eptinezumab met the primary endpoint and key secondary endpoints in PROMISE 1 with very high statistical significance. See the press release for more information.
PROMISE 2 (PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy 2) is a Phase 3, randomized, double-blind, placebo-controlled global trial evaluating the safety and efficacy of eptinezumab for chronic migraine prevention. In the study, patients were randomized and 1,072 received eptinezumab (300 mg or 100 mg), administered by infusion once every 12 weeks. To be eligible for the trial, patients must have experienced at least 15 headache days per month, of which at least eight met criteria for migraine. Patients that participated in the trial had an average of 16.1 migraine days per month at baseline. The primary endpoint was the mean change from baseline in monthly migraine days over the 12 week, double-blind treatment period. Secondary study endpoints assessed through 12 weeks included proportion of patients experiencing migraine on the day following administration 6 and reduction of migraine prevalence days 1-28, reduction of at least 50%, 75%, and 100% from baseline in mean monthly migraine days, change from baseline in mean monthly acute migraine-specific medication days, and reductions from baseline in patient-reported impact scores on the Headache Impact Test (HIT-6). In January 2018, Alder announced that eptinezumab met the primary endpoint and key secondary endpoints in PROMISE 2 with very high statistical significance. See the press release for more information.
Migraine affects 36 million Americans1 and, worldwide, is considered the sixth-leading cause of days with disability4 and the third-leading cause of disability of people under the age of 50.7 The occurrence of migraine can be unpredictable with a profound impact on activities of daily living. This disease can last decades, often during what should be the most productive years of patients’ lives.3 Migraine can remit or progress to chronic migraine over time and persist as chronic migraine for years or decades, but it commonly oscillates between periods of frequent episodic and chronic migraine. Current preventive treatments for migraine fail to meet the needs of most patients and most patients discontinue use within 6 months to 1 year due to lack of efficacy and/or side effects.3,4,8 There is a significant need for new, effective, and well-tolerated treatment options.
This press release contains forward-looking statements, including, without limitation, statements relating to: the continued development and clinical, therapeutic and commercial potential of eptinezumab eptinezumab’s potential to be an important treatment option in migraine prevention; the impact of the referenced data and results presented; and the significant need for new treatment options. Words such as “demonstrate,” “encouraging,” “showing,” “reinforce,” “confidence,” “option,” “validate,” “underscore,” “commitment,” “can,” “look forward,” “promise,” “potential;” “may,” “need,” or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Alder's current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder’s development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption "Risk Factors" in Alder's Quarterly Report on Form 10-Q for the quarterly period ended
Investor Relations Contact:
Vice President, Corporate Strategy
Stern Investor Relations, Inc.
* Eptinezumab’s efficacy was not statistically compared against Placebo.
2 Parsekyan D. Migraine prophylaxis in adult patients. West J Med. 2000;173(5):341-345.
3 Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):477-488.
4 Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55(S2):103-122.
5 Baker B, Schaeffler B, Cady R, et al. Rational design of a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, ALD403 (Eptinezumab), intended for the prevention of migraine. Poster presented at:
6 Day One prevalence rate comparison between eptinezumab vs. placebo.
7 Steiner, TJ, Stovner, LJ, & Vos, T. GBD 2015: Migraine is the third cause of disability in under 50s.
8 Bigal ME, Krymchantowski AV, Lipton RB. Barriers to satisfactory migraine outcomes. What have we learned, where do we Stand? Headache. 2009;49(7):1028—1041.
Source: Alder BioPharmaceuticals, Inc.